Featured News
406Wire StoriesParade Technologies Offers Best-in-class latency for CXL Retimer Solutions
Parade’s PS8936 offers latencies that are only a fraction of those of the competition SAN JOSE, Calif.–(BUSINESS WIRE)–Parade Technologies, Ltd. (Taiwan OTC:...
- 494News
AI Singapore Awards S$20M in Research Funds to Address Challenges Relating to Increase Use of AI in Emerging Apps
Research outcomes have potential for dual-use applications, for leverage by both the industry & defence SINGAPORE – Media OutReach – 26 July...
- 442News
Nut Techy Launches “Computing Power Investment” to Boost Business Market Value and User Base
SINGAPORE – Media OutReach – 26 July 2023 – Recently, well-known computing power operator Nut Techy launched a new business called “Computing...
- 539Wire Stories
LogicMonitor Expands Relationship With AWS
More monitoring coverage across services and enhanced capabilities with AWS leads to cost savings, better uptime and improved visibility into business changes...
- 453Wire Stories
Recent Cash Injection Boosts VectorBuilder to Unicorn Status
CHICAGO–(BUSINESS WIRE)–Gene delivery technologies are turning into the next big-ticket item globally, as the most recent investment received by VectorBuilder Inc., a...
- 493Wire Stories
Endace Scalable Packet Capture Delivers Unified Visibility Across Hybrid Cloud
EndaceProbe Cloud provides scalable packet capture for unified visibility across on-premise, private-cloud and public cloud environments AUCKLAND, New Zealand & AUSTIN, Texas–(BUSINESS...
- 708Wire Stories
Nickel 28 Releases Ramu Q2 2023 Operating Performance
TORONTO–(BUSINESS WIRE)–$NKL #mining–Nickel 28 Capital Corp. (“Nickel 28†or the “Companyâ€) (TSXV: NKL) (FSE: 3JC0) is pleased to provide operational results for...
- 492Wire Stories
Identiv Starts Production at New Facility in Bangkok, Thailand
New Production Facility Meets Growing Demand for IoT Solutions FREMONT, Calif.–(BUSINESS WIRE)–Identiv, Inc. (Nasdaq: INVE), a global digital security and identification leader...
- 611Wire Stories
Merck and Moderna Initiate Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Resected High-Risk (Stage IIB-IV) Melanoma
V940-001 is the first Phase 3 study of a planned comprehensive clinical development program being initiated following the positive primary analysis of...
- 731Wire Stories
UMC Reports Second Quarter 2023 Results
Company’s differentiating specialty technologies accounted for 59% of Q2 revenue Solid 22/28nm business momentum lifted contribution to 29% Second Quarter 2023 Overview1:...
- 502News
AXA and AXA XL partner with Lutheran School and Ebenezer School to create wonderful dragon boat experience for hearing and visually impaired students
HONG KONG SAR – Media OutReach – 26 July 2023 – AXA Hong Kong and Macau (“AXA”) and AXA XL organised two...
